Skip to main content
. Author manuscript; available in PMC: 2022 Dec 15.
Published in final edited form as: Eur J Pharmacol. 2021 Nov 5;913:174619. doi: 10.1016/j.ejphar.2021.174619

Fig. 4.

Fig. 4.

The expression of ERK1/2 (A, B) and p-ERK1/2 (C, D) in the L4-L5 spinal dorsal horn in the comorbid pain condition. The expression of ERK1/2 in the E2 + CFA + FS group (n = 4) did not significantly change compared with the oil + saline + non-FS group (n = 6). The expression of p-ERK1/2 in the E2 + CFA + FS group significantly increased compared with the oil + saline + non-FS group. Data were normalized to the oil + saline + non-FS group. *P < 0.05 vs. the oil + saline + non-FS group.